Compare
Corcept Therapeutics vs Lilly (Eli) (CORT vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Corcept Therapeutics (CORT) returned -5.1% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are +109.1% and +26.0%.
Lilly (Eli) is the larger company by market value, about 160.0 times the size of Corcept Therapeutics.
On trailing earnings, CORT trades at 57.3 times and LLY at 43.9 times.
Revenue grew +30.0% at CORT and +45.5% at LLY over the last year.
CORT pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| CORT | LLY | |
|---|---|---|
| Price | $72.77 | $1,354.00 |
| 1-day | +1.59% | -0.79% |
| YTD | +109.11% | +25.99% |
| 1 year | -5.06% | +46.25% |
| 3 years | +159.06% | +144.20% |
| Market cap | $8.0B | $1.27T |
| P/E | 57.3 | 43.9 |
| P/S | 8.26 | 14.73 |
| P/B | 9.55 | 31.63 |
| Revenue growth | +30.00% | +45.50% |
| EPS growth | +46.00% | +50.70% |
| Gross margin % | 98.5 | 83.6 |
| Net margin % | 16.8 | 31.9 |
| ROE % | 19.5 | 68.5 |
| Debt / equity | 0.00 | 1.23 |
| FCF yield % | 2.4 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 1.96 | 0.29 |
| RSI (14) | 22.0 | 61.1 |
| Technical rating |